Where Will Dell Stock Be in 5 Years?
So you’re looking at Dell (NASDAQ: DELL) and wondering, “Is…
Sell
50
MRM Quote, Financials, Valuation and Earnings
Last price:
$1.55
Seasonality move
:
-22.37%
Day range:
$1.25 - $1.48
52-week range:
$0.34 - $8.39
Dividend yield:
0%
P/E ratio:
7.13x
P/S ratio:
0.16x
P/B ratio:
1.93x
Volume:
154K
Avg. volume:
580.5K
1-year change:
-73.07%
Market cap:
$11.5M
Revenue:
$54.9M
EPS (TTM):
-$0.12
Analysts' Opinion
-
Consensus RatingMEDIROM Healthcare Technologies has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $4.98, MEDIROM Healthcare Technologies has an estimated upside of 243.21% from its current price of $1.45.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $4.98 representing 100% downside risk from its current price of $1.45.
Fair Value
-
According to the consensus of 1 analyst, MEDIROM Healthcare Technologies has 243.21% upside to fair value with a price target of $4.98 per share.
MRM vs. S&P 500
-
Over the past 5 trading days, MEDIROM Healthcare Technologies has underperformed the S&P 500 by -19.92% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
MEDIROM Healthcare Technologies does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
MEDIROM Healthcare Technologies has grown year-over-year revenues for 0 quarters straight. In the most recent quarter MEDIROM Healthcare Technologies reported revenues of --.
Earnings Growth
-
MEDIROM Healthcare Technologies has grown year-over-year earnings for 0 quarters straight. In the most recent quarter MEDIROM Healthcare Technologies reported earnings per share of --.
Enterprise value:
22.9M
EV / Invested capital:
--
Price / LTM sales:
0.16x
EV / EBIT:
31.88x
EV / Revenue:
0.42x
PEG ratio (5yr expected):
0.36x
EV / Free cash flow:
-1.86x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
8.84x
Gross Profit (TTM):
$10.2M
Return On Assets:
-1.31%
Net Income Margin (TTM):
-1.17%
Return On Equity:
--
Return On Invested Capital:
-6.44%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-05-30 | 2024-05-30 | 2024-05-30 | |||
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -- | -- | -- | -- | -- | |
| EBITDA | -- | -- | -- | -- | -- | |
| Diluted EPS | -- | -- | -- | -- | -- | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $20.2M | $12M | $18M | $12.5M | $17.2M | |
| Total Assets | $55.4M | $50M | $51.5M | $48.6M | $51.5M | |
| Current Liabilities | $25.7M | $27.8M | $27.8M | $25.2M | $26.6M | |
| Total Liabilities | $50.6M | $51.8M | $51.9M | $47M | $44M | |
| Total Equity | $4.8M | -$1.8M | -$452.9K | $1.5M | $7.6M | |
| Total Debt | $8.8M | $7.9M | $9.5M | $11M | $12M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-05-30 | 2024-05-30 | 2024-05-30 | |||
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -- | -- | -- | -- | |
| Cash From Investing | -- | -- | -- | -- | -- | |
| Cash From Financing | -- | -- | -- | -- | -- | |
| Free Cash Flow | -- | -- | -- | -- | -- | |
MRM
Sector
Market Cap
$11.5M
$408.5M
Price % of 52-Week High
17.31%
71.08%
Dividend Yield
0%
0%
Shareholder Yield
--
3.91%
1-Year Price Total Return
-73.07%
-12.47%
Beta (5-Year)
--
0.782
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$1.38
200-day SMA
Sell
Level
$1.89
Bollinger Bands (100)
Buy
Level
0.58 - 1.1
Chaikin Money Flow
Sell
Level
-37.7M
20-day SMA
Buy
Level
$1.06
Relative Strength Index (RSI14)
Buy
Level
61.58
ADX Line
Buy
Level
37.09
Williams %R
Neutral
Level
-44.17
50-day SMA
Buy
Level
$0.81
MACD (12, 26)
Buy
Level
0.18
25-day Aroon Oscillator
Buy
Level
68
On Balance Volume
Neutral
Level
185.8M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (1.0379)
Sell
CA Score
(Annual)
Level (-1.9309)
Sell
Beneish M-Score
(Annual)
Level (-0.8812)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (4.1529)
Buy
Piotroski F Score
(Annual)
Level (7)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
MEDIROM Healthcare Technologies Inc provides health services. The company is a franchiser and operator of healthcare salons and operates in segments namely Relaxation Salon, Digital Preventative Healthcare, and Luxury Beauty Segment. The company generates a majority of its revenue from the Relaxation Salon business segment. Geographically, the company generates a maximum share of its revenue from Japan.
Stock Forecast FAQ
In the current month, MRM has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The MRM average analyst price target in the past 3 months is $4.98.
-
Where Will MEDIROM Healthcare Technologies Stock Be In 1 Year?
According to analysts, the consensus estimate is that MEDIROM Healthcare Technologies share price will rise to $4.98 per share over the next 12 months.
-
What Do Analysts Say About MEDIROM Healthcare Technologies?
Analysts are divided on their view about MEDIROM Healthcare Technologies share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that MEDIROM Healthcare Technologies is a Sell and believe this share price will drop from its current level to $4.98.
-
What Is MEDIROM Healthcare Technologies's Price Target?
The price target for MEDIROM Healthcare Technologies over the next 1-year time period is forecast to be $4.98 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is MRM A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for MEDIROM Healthcare Technologies is a Buy. 1 of 1 analysts rates the stock a Buy at this time.
-
How Can I Buy Shares Of MRM?
You can purchase shares of MEDIROM Healthcare Technologies via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase MEDIROM Healthcare Technologies shares.
-
What Is The MEDIROM Healthcare Technologies Share Price Today?
MEDIROM Healthcare Technologies was last trading at $1.55 per share. This represents the most recent stock quote for MEDIROM Healthcare Technologies. Yesterday, MEDIROM Healthcare Technologies closed at $1.45 per share.
-
How To Buy MEDIROM Healthcare Technologies Stock Online?
In order to purchase MEDIROM Healthcare Technologies stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will Cameco Stock Be in 5 Years?
Cameco (NYSE: CCJ) isn’t exactly the kind of stock you…
Microsoft Stock Outlook, Azure & AI as Drivers of Long-Term Growth
Microsoft (NASDAQ:MSFT) has been among the top growth stocks of…
Stock Ideas
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 39x
Buy
70
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 47x
Sell
39
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Buy
84
SBET alert for May 30
SharpLink Gaming [SBET] is down 0.32% over the past day.
Buy
55
RGC alert for May 30
Regencell Bioscience Holdings [RGC] is up 21.66% over the past day.
Buy
73
CTEV alert for May 30
Claritev [CTEV] is up 5.01% over the past day.
